Shalby profit falls 24.95% QoQ despite a 0.66-point margin gain
Expenses fell faster than revenue, but higher interest, lower other income and a 52.13% tax rate pulled down consolidated net profit.
Filed 03 Nov 2026, 18:12 IST · after market close · Shalby Ltd (SHALBY)
Key takeaways
- Consolidated net profit fell 24.95% QoQ to Rs 7.88 cr as the tax rate rose 5.42 percentage points to 52.13%.
- Operating margin improved by 0.66 percentage points to 13.22% because expenses declined 6.16% against a 5.45% fall in revenue.
- Other income contributed 30.6% of consolidated pre-tax profit, while operating margin remained 8.02 percentage points below the healthcare-peer median across 56 reporters.
Price around the results
Operating profit held up as revenue softened
Consolidated revenue declined 5.45% QoQ to Rs 313.17 cr, while operating profit slipped only 0.46% to Rs 41.4 cr. Expenses fell 6.16%, faster than revenue, lifting operating margin by 0.66 percentage points to 13.22%. Profit before tax still fell 16.40% because interest rose 4.64% and other income declined 31.98%.
Tax and other income weakened profit quality
The tax rate increased by 5.42 percentage points to 52.13%, adding to the pressure on net profit. Other income was 30.6% of pre-tax profit, so the Rs 7.88 cr reported profit included a material non-operating contribution. At 13.22%, operating margin was 8.02 percentage points below the 21.24% median for 56 healthcare peers that had reported the quarter.
Management links capacity and process work to growth plans
Management said implant-processing volumes through its Clean, Pack & Sterile department supported product availability and revenue growth, while fewer quality-control non-conformances reduced rework. The company said it is recommissioning a secondary clean line, restoring an in-house passivation line and pursuing process-efficiency measures to expand capacity and reduce bottlenecks. Management also said it is diversifying into cardiac science, oncology, neuroscience, critical care, general medicine and transplants, alongside 24x7 homecare services outside its hospitals.
Results were filed after market close
The consolidated results were filed after market close, so this note does not include a market reaction. Sequentially, operating margin improved from 12.56% in Q1FY27 to 13.22%, but net profit fell from Rs 10.5 cr to Rs 7.88 cr as the higher tax rate and weaker other income outweighed the operating-margin gain.
Q2FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q2FY27 | Q1FY27 | QoQ |
|---|---|---|---|
| Revenue | ₹313 cr | ₹331 cr | -5.45% |
| Other income | ₹5 cr | ₹7 cr | -31.98% |
| Expenses | ₹272 cr | ₹290 cr | -6.16% |
| Operating profit | ₹41 cr | ₹42 cr | -0.46% |
| Operating margin (%) | 13.22% | 12.56% | — |
| Interest | ₹11 cr | ₹11 cr | +4.64% |
| Depreciation | ₹19 cr | ₹19 cr | +0.96% |
| Profit before tax | ₹16 cr | ₹20 cr | -16.40% |
| Tax | ₹9 cr | ₹9 cr | -6.63% |
| Net profit | ₹8 cr | ₹11 cr | -24.95% |
| EPS (₹) | ₹0.73 | ₹0.98 | -25.51% |
Operating margin of 13.22% compares with a Healthcare sector median of 21.24% across 56 peers that have reported Q2FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Implant processing volumes grew through the Clean, Pack & Sterile department, supporting product availability and revenue growth.
- Quality-control non-conformances decreased, improving first-pass acceptance, reducing rework and enhancing production efficiency.
Guidance & outlook
- Shalby aims to maintain global leadership in joint replacements.
Expansion
- Shalby is recommissioning a secondary clean line to expand production capacity and support growing demand.
New initiatives
- Shalby is diversifying into cardiac science, oncology, neuroscience, critical care, general medicine and transplants.
- Shalby is developing 24x7 homecare services outside its hospital locations.
- Shalby has implemented process-efficiency initiatives to increase operational throughput and scalability.
- Shalby commenced targeted surgeon engagement initiatives to increase utilization and market adoption.
Competition
- Shalby describes itself as a global leader in joint replacement.
Problems & risks
- Shalby identified defects and scrap from contract manufacturers as sources of material losses and lower yields.
- Shalby identified production bottlenecks that are being addressed through in-house processing capabilities.
What to watch
- Whether operating margin holds above 13.22% as revenue moves from Rs 313.17 cr.
- Whether the tax rate falls from 52.13% and net profit improves from Rs 7.88 cr.
- Whether the capacity and process-efficiency initiatives cited by management support revenue without eroding the 13.22% operating margin.